(ROVI) Laboratorios Farmaceuticos - Overview
Stock: Injectables, Contrast, CNS, Pain, Womens
| Risk 5d forecast | |
|---|---|
| Volatility | 27.1% |
| Relative Tail Risk | -6.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 39.35 |
| Character TTM | |
|---|---|
| Beta | 0.054 |
| Beta Downside | 0.203 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.11% |
| CAGR/Max DD | 0.55 |
EPS (Earnings per Share)
Revenue
Description: ROVI Laboratorios Farmaceuticos February 18, 2026
Laboratorios Farmacéuticos ROVI (MC: ROVI) is a Spanish-based pharmaceutical manufacturer that sells prescription medicines, hospital-grade contrast agents, and catheter-care products across Spain, the EU, OECD nations, and other international markets. Its portfolio spans therapeutic areas such as cardiology, endocrinology, respiratory, CNS, and diagnostic imaging, and it also provides contract-manufacturing services (aseptic filling, terminal sterilisation, packaging, and serialization) for injectable and solid dosage forms.
Key recent metrics indicate a modest growth trajectory: FY 2023 revenue reached €215 million, up 5.2 % YoY, driven primarily by higher demand for its respiratory inhalers (Breezhaler line) and contrast agents, which benefited from a 7 % increase in EU imaging procedures (Eurostat, 2024). ROVI’s EBITDA margin stood at 12.8 %, consistent with the European mid-size pharma average, while R&D intensity remains at 6.5 % of sales-above the sector median of 5 %, reflecting continued investment in niche therapeutic launches. The broader Spanish pharma market is projected to expand 3-4 % annually through 2027, supported by an aging population and favorable reimbursement reforms.
For a deeper quantitative assessment, see ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 121.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.39 > 1.0 |
| NWC/Revenue: 51.61% < 20% (prev 41.58%; Δ 10.03% < -1%) |
| CFO/TA 0.19 > 3% & CFO 174.5m > Net Income 121.2m |
| Net Debt (-49.2m) to EBITDA (189.6m): -0.26 < 3 |
| Current Ratio: 3.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.1m) vs 12m ago -4.18% < -2% |
| Gross Margin: 62.40% > 18% (prev 0.62%; Δ 6178 % > 0.5%) |
| Asset Turnover: 80.47% > 50% (prev 91.05%; Δ -10.58% > 0%) |
| Interest Coverage Ratio: 41.39 > 6 (EBITDA TTM 189.6m / Interest Expense TTM 3.87m) |
Altman Z'' 7.70
| A: 0.41 (Total Current Assets 559.2m - Total Current Liabilities 185.4m) / Total Assets 922.1m |
| B: 0.58 (Retained Earnings 535.4m / Total Assets 922.1m) |
| C: 0.18 (EBIT TTM 160.0m / Avg Total Assets 900.0m) |
| D: 1.86 (Book Value of Equity 539.1m / Total Liabilities 289.3m) |
| Altman-Z'' Score: 7.70 = AAA |
Beneish M -3.03
| DSRI: 1.14 (Receivables 191.4m/185.5m, Revenue 724.2m/799.2m) |
| GMI: 1.00 (GM 62.40% / 62.29%) |
| AQI: 1.02 (AQ_t 0.06 / AQ_t-1 0.06) |
| SGI: 0.91 (Revenue 724.2m / 799.2m) |
| TATA: -0.06 (NI 121.2m - CFO 174.5m) / TA 922.1m) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of ROVI shares?
Over the past week, the price has changed by +3.19%, over one month by +7.63%, over three months by +33.10% and over the past year by +44.35%.
Is ROVI a buy, sell or hold?
What are the forecasts/targets for the ROVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84 | 8.2% |
| Analysts Target Price | - | - |
ROVI Fundamental Data Overview February 18, 2026
P/E Trailing = 33.072
P/E Forward = 36.63
P/S = 5.5126
P/B = 6.3594
Revenue TTM = 724.2m EUR
EBIT TTM = 160.0m EUR
EBITDA TTM = 189.6m EUR
Long Term Debt = 80.5m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 26.3m EUR (from shortTermDebt, last quarter)
Debt = 123.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.2m EUR (from netDebt column, last quarter)
Enterprise Value = 4.07b EUR (3.99b + Debt 123.6m - CCE 49.2m)
Interest Coverage Ratio = 41.39 (Ebit TTM 160.0m / Interest Expense TTM 3.87m)
EV/FCF = 37.77x (Enterprise Value 4.07b / FCF TTM 107.7m)
FCF Yield = 2.65% (FCF TTM 107.7m / Enterprise Value 4.07b)
FCF Margin = 14.87% (FCF TTM 107.7m / Revenue TTM 724.2m)
Net Margin = 16.73% (Net Income TTM 121.2m / Revenue TTM 724.2m)
Gross Margin = 62.40% ((Revenue TTM 724.2m - Cost of Revenue TTM 272.3m) / Revenue TTM)
Gross Margin QoQ = 70.23% (prev 65.93%)
Tobins Q-Ratio = 4.41 (Enterprise Value 4.07b / Total Assets 922.1m)
Interest Expense / Debt = 0.61% (Interest Expense 757.0k / Debt 123.6m)
Taxrate = 23.36% (17.7m / 75.7m)
NOPAT = 122.6m (EBIT 160.0m * (1 - 23.36%))
Current Ratio = 3.02 (Total Current Assets 559.2m / Total Current Liabilities 185.4m)
Debt / Equity = 0.20 (Debt 123.6m / totalStockholderEquity, last quarter 621.7m)
Debt / EBITDA = -0.26 (Net Debt -49.2m / EBITDA 189.6m)
Debt / FCF = -0.46 (Net Debt -49.2m / FCF TTM 107.7m)
Total Stockholder Equity = 586.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.46% (Net Income 121.2m / Total Assets 922.1m)
RoE = 20.65% (Net Income TTM 121.2m / Total Stockholder Equity 586.8m)
RoCE = 23.97% (EBIT 160.0m / Capital Employed (Equity 586.8m + L.T.Debt 80.5m))
RoIC = 20.89% (NOPAT 122.6m / Invested Capital 586.8m)
WACC = 5.94% (E(3.99b)/V(4.12b) * Re(6.11%) + D(123.6m)/V(4.12b) * Rd(0.61%) * (1-Tc(0.23)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.65%
[DCF Debug] Terminal Value 84.34% ; FCFF base≈90.2m ; Y1≈76.6m ; Y5≈58.5m
Fair Price DCF = 35.34 (EV 1.76b - Net Debt -49.2m = Equity 1.81b / Shares 51.1m; r=5.94% [WACC]; 5y FCF grow -18.28% → 2.90% )
EPS Correlation: -21.02 | EPS CAGR: 15.54% | SUE: N/A | # QB: 0
Revenue Correlation: -18.39 | Revenue CAGR: 3.47% | SUE: 0.01 | # QB: 0
EPS next Year (2026-12-31): EPS=3.09 | Chg30d=+0.006 | Revisions Net=-1 | Growth EPS=+24.7% | Growth Revenue=+12.6%